Alloy Genetic Medicines' AntiClastic platform engineers antisense oligonucleotides, siRNAs, and sgRNAs into proprietary cyclic architectures claimed to boost potency, stability, and patient safety versus linear designs.
An Oligonucleotide Design Studio combining AI modeling, machine learning, and human expertise screens hundreds of thousands of sequences in silico for target affinity and developability, delivered to drug developers through partnerships such as the Biogen multi-target collaboration.

AI-guided cyclic-oligonucleotide platform for designing ASO, siRNA, and sgRNA drug candidates.


Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.


Strategic partnership and collaboration offering applying Creyon's RNA platform to partner disease areas.


NucleIQ is Creyon's AI-powered nucleic acid engineering platform for designing oligonucleotide-based medicines.
Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.

Strategic partnership and collaboration offering applying Creyon's RNA platform to partner disease areas.

NucleIQ is Creyon's AI-powered nucleic acid engineering platform for designing oligonucleotide-based medicines.



Foundation-model platform for designing sequence-based medicines including siRNA, ASO, mRNA, and peptides.


Antisense oligonucleotide portfolio for neurological disease including spinal muscular atrophy and ALS.



Allosteric screening and synthetic lethality platforms with 200k library.


Antibody-oligonucleotide conjugate platform delivering siRNA and PMO payloads to muscle, cardiac, and immune cells.


Med-Oligo is AusperBio's antisense oligonucleotide design platform using positioned chemical modifications for higher potency.


STELLAR is Copernicus Therapeutics' non-viral gene delivery platform for compacted DNA nanoparticles.


Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
Foundation-model platform for designing sequence-based medicines including siRNA, ASO, mRNA, and peptides.

Antisense oligonucleotide portfolio for neurological disease including spinal muscular atrophy and ALS.

Agentic AI platform for RNA drug discovery covering ASO and siRNA design through lead optimization.

Allosteric screening and synthetic lethality platforms with 200k library.

Antibody-oligonucleotide conjugate platform delivering siRNA and PMO payloads to muscle, cardiac, and immune cells.

Med-Oligo is AusperBio's antisense oligonucleotide design platform using positioned chemical modifications for higher potency.

STELLAR is Copernicus Therapeutics' non-viral gene delivery platform for compacted DNA nanoparticles.

Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
